



PTO/SB/08a (11-08)

Approved for use through 12/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	3	Attorney Docket Number	401.1013US
-------	---	----	---	------------------------	------------

Complete If Known

Application Number	10/500,964
Filing Date	July 8, 2004
First Named Inventor	Keizo SUGASAWA
Art Unit	1625
Examiner Name	C. C. Chang
Attorney Docket Number	401.1013US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1*	US-20040073029	04-15-2004	Pruitt et al.	
	A2*	US-20040122235	06-24-2004	Polisetti et al.	
	A3*	US-20040235834	11-25-2004	Farmer et al.	
	A4*	US-6,962,935	11-08-2005	Pruitt et al.	
	A5*	US-7,384,967	06-10-2008	Polisetti et al.	
	A6*	US-6,040335	03-21-2000	SAITOH MASAYUKI et al.	
	A7*	US-5,583,131	12-10-1996	BRIDGER GARY JAMES et al.	
	A8*	US-6,083,913	07-04-2000	DOWER WILLIAM J et al.	
	A9*	US-6,498,155	12-24-2002	LUENGO JUAN I et al.	
	A10*	US-5,963,666	10-05-1999	FUJISAKI TETSUNOSUKE et al.	
	A11*	US-5,384,331	01-24-1995	KOGAN TIMOTHY P et al.	
	A12*	US-5,932,546	08-03-1999	BARRETT RONALD W et al.	
	A13*	US-5,728,709	03-17-1998	IKUINA YOJI et al.	
	A14*	US-5,314,889	05-24-1994	Biogegrain, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	EP-0518731-B1	08-26-1998	Sanofi SA		Abstr. (See also US 5,314,889)
	B2	WO-02/053160-A1	07-11-2002	Alteon, Inc.		
	B3	WO-03/075921-A2	09-18-2003	Transtech Pharma, Inc.		
	B4	WO-03/084544-A2	10-16-2003	CV Therapeutics, Inc.		
	B5	WO-04/002481-A1	01-08-2004	Novo Nordisk A/S		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with a single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Complete if Known

Attorney Docket Number	401.1013US
------------------------	------------

Sheet	2	of	3
-------	---	----	---

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)				
	B6	WO-04/071447-A3	08-26-2004	Transtech Pharma Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/500,964
				Filing Date	July 8, 2004
				First Named Inventor	Keizo SUGASAWA
				Art Unit	1625
				Examiner Name	C. C. Chang
Sheet	3	of	3	Attorney Docket Number	401.1013US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Braga, Dario et al., "Making crystals from crystals: a green route to crystal engineering and polymorphism," <i>Chem. Commun.</i> , Vol. 29:3635-3645 (2005)	
	C2	Morissette, Sherry et al., "High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids," <i>Advanced Drug Delivery Reviews</i> , Vol. 56:275-300 (2004)	
	C3	Vippagunta, Sudha et al., "Crystalline solids," <i>Advanced Drug Delivery Reviews</i> , Vol. 48:3-26 (2001) (Abstract)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.